Improving Bone Health by Optimizing the Anabolic Action of Wnt Inhibitor Multitargeting

ABSTRACT Sclerostin antibody (romosozumab) was recently approved for clinical use in the United States to treat osteoporosis. We and others have explored Wnt‐based combination therapy to disproportionately improve the anabolic effects of sclerostin inhibition, including cotreatment with sclerostin a...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Roy B Choi, Whitney A Bullock, April M Hoggatt, Gabriela G Loots, Damian C Genetos, Alexander G Robling
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Oxford University Press 2021-05-01
coleção:	JBMR Plus
Assuntos:	BONE ANABOLISM OSTEOPOROSIS SCLEROSTIN Dkk1 Wnt
Acesso em linha:	https://doi.org/10.1002/jbm4.10462
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!